IF0 Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
InflaRx N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.38 |
| 52 Week High | US$1.96 |
| 52 Week Low | US$1.08 |
| Beta | 1.58 |
| 11 Month Change | -0.29% |
| 3 Month Change | 8.18% |
| 1 Year Change | 16.22% |
| 33 Year Change | -69.73% |
| 5 Year Change | -35.09% |
| Change since IPO | -89.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| IF0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.1% | 0.7% | 1.1% |
| 1Y | 16.2% | -17.7% | 12.5% |
Return vs Industry: IF0 exceeded the German Biotechs industry which returned -17.7% over the past year.
Return vs Market: IF0 exceeded the German Market which returned 12.5% over the past year.
Price Volatility
| IF0 volatility | |
|---|---|
| IF0 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IF0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IF0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 62 | Niels Riedemann | www.inflarx.de |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
InflaRx N.V. Fundamentals Summary
| IF0 fundamental statistics | |
|---|---|
| Market cap | €82.35m |
| Earnings (TTM) | -€46.88m |
| Revenue (TTM) | €105.48k |
780.7x
P/S Ratio-1.8x
P/E RatioIs IF0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IF0 income statement (TTM) | |
|---|---|
| Revenue | €105.48k |
| Cost of Revenue | €1.10m |
| Gross Profit | -€995.45k |
| Other Expenses | €45.89m |
| Earnings | -€46.88m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | -0.80 |
| Gross Margin | -943.71% |
| Net Profit Margin | -44,447.49% |
| Debt/Equity Ratio | 0% |
How did IF0 perform over the long term?
See historical performance and comparison